Dysregulated Immune Responses in COVID-19 Patients Correlating With Disease Severity and Invasive Oxygen Requirements.
Aged
Antibodies, Viral
/ blood
COVID-19
/ immunology
Convalescence
Disease Progression
Eosinophils
/ immunology
Female
Humans
Immunity, Cellular
Immunoglobulin G
/ blood
Immunologic Memory
Male
Middle Aged
Plasma Cells
/ immunology
SARS-CoV-2
/ physiology
Severity of Illness Index
Th1 Cells
/ immunology
immunity
immunological memory
invasive mechanical ventilation
oxygen therapy
severe COVID-19
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
09
2021
accepted:
05
10
2021
entrez:
8
11
2021
pubmed:
9
11
2021
medline:
26
11
2021
Statut:
epublish
Résumé
The prognosis of severe COVID-19 patients has motivated research communities to uncover mechanisms of SARS-CoV-2 pathogenesis also on a regional level. In this work, we aimed to understand the immunological dynamics of severe COVID-19 patients with different degrees of illness, and upon long-term recovery. We analyzed immune cellular subsets and SARS-CoV-2-specific antibody isotypes of 66 COVID-19 patients admitted to the Hospital Clínico Universidad de Chile, which were categorized according to the WHO ten-point clinical progression score. These included 29 moderate patients (score 4-5) and 37 severe patients under either high flow oxygen nasal cannula (18 patients, score 6), or invasive mechanical ventilation (19 patients, score 7-9), plus 28 convalescent patients and 28 healthy controls. Furthermore, six severe patients that recovered from the disease were longitudinally followed over 300 days. Our data indicate that severe COVID-19 patients display increased frequencies of plasmablasts, activated T cells and SARS-CoV-2-specific antibodies compared to moderate and convalescent patients. Remarkably, within the severe COVID-19 group, patients rapidly progressing into invasive mechanical ventilation show higher frequencies of plasmablasts, monocytes, eosinophils, Th1 cells and SARS-CoV-2-specific IgG than patients under high flow oxygen nasal cannula. These findings demonstrate that severe COVID-19 patients progressing into invasive mechanical ventilation show a distinctive type of immunity. In addition, patients that recover from severe COVID-19 begin to regain normal proportions of immune cells 100 days after hospital discharge and maintain high levels of SARS-CoV-2-specific IgG throughout the study, which is an indicative sign of immunological memory. Thus, this work can provide useful information to better understand the diverse outcomes of severe COVID-19 pathogenesis.
Identifiants
pubmed: 34745145
doi: 10.3389/fimmu.2021.769059
pmc: PMC8567168
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
769059Informations de copyright
Copyright © 2021 García-González, Tempio, Fuentes, Merino, Vargas, Simon, Ramirez-Pereira, Rojas, Tobar, Landskron, Araya, Navarrete, Bastias, Tordecilla, Varas, Maturana, Marcoleta, Allende, Naves, Hermoso, Salazar-Onfray, Lopez, Bono and Osorio.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Rev Clin Esp (Barc). 2021 Feb;221(2):109-117
pubmed: 33998486
Sci Immunol. 2020 Sep 17;5(51):
pubmed: 32943497
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Science. 2021 May 28;372(6545):
pubmed: 33906968
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
PLoS Pathog. 2020 Apr 28;16(4):e1008520
pubmed: 32343745
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
J Infect Chemother. 2021 Aug;27(8):1217-1222
pubmed: 34023221
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
Front Immunol. 2020 Feb 11;10:3154
pubmed: 32117210
Cell. 2020 Sep 3;182(5):1077-1092
pubmed: 32846157
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Adv Immunol. 2016;131:61-99
pubmed: 27235681
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Lancet. 2020 Nov 7;396(10261):1525-1534
pubmed: 32979936
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Clin Med. 2020 Jun 05;9(6):
pubmed: 32516940
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524